Tubulis GmbH
Booth number 4607-08Tubulis generates uniquely matched Antibody Drug Conjugates (ADCs) based on proprietary and broadly patent protected next-generation conjugation and linker-payload platforms.
About us
Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.
Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.
Address
Tubulis GmbH
Butenandtstr. 1
81375 Munich
Germany
Phone: +49 1723 505125
Internet: www.tubulis.com
Products and Services
Pipeline
We are currently advancing three ADC assets:
TUB-010 | Lymphoma, pre-IND; ready for partnering
TUB-030 | solid cancer, discovery
TUB-040 | solid cancer, discovery
Strong technology portfolio
Tub-tag and P5 by Tubulis - one company, two unique, complementing ADC conjugation technologies fulfilling the needs of 3rd generation ADCs:
- ADC Homogeneity leading to mAb-like ADC properties
- Linker Stability ensuring safe delivery
- High DAR flexibility enabling unique antibody-payload combinations.
- Chemical flexibility giving access to novel payload classes
Focus at this meeting is to explore opportunities for:
1) Development & commercialization partnerships for TUB-010 our IND-ready ADC for lymphomas, targeting CD30
2) Pharma partnerships for novel ADCs
Keywords: CD30, cancer, oncology, ADC, solid tumors, lymphoma, novel linkers & payloads
Click here if you notice an image that violates copyright or privacy rights.